Developer docs
API playgroundTry for free, no card

Search company profiles

GentiBio

Full company profile

uuid0000n6f

Namestring
GentiBio
Legal namestring
GentiBio, Inc.
Websiteurl
gentibio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

GentiBio is a clinical-stage biopharmaceutical company developing engineered regulatory T cell (EngTreg) therapies to treat autoimmune and inflammatory diseases, with its lead candidate GNTI-122 currently in the Phase 1 POLARIS trial for recently diagnosed Type 1 Diabetes. The company's scientific foundation rests on a modular EngTreg platform that combines three technology pillars: targeting via CAR, TCR, or chemokine receptors for disease-site specificity; constitutive FOXP3 expression to lock in a durable Treg phenotype in inflammatory environments; and a proprietary Chimeric IL-2 Signaling Complex (CISC) that provides IL-2 survival support specifically to engineered cells. The platform extends to an off-the-shelf allogeneic format enabled by Immune Evasion Engineering (HLA knock-out combined with a proprietary NK inhibitor) and a scalable manufacturing system that delivers >10^9 autologous cells at >90% purity in two weeks or thousands of allogeneic doses per batch at low-thousands-of-dollars COGS. The pipeline includes GNTI-122 (autologous, T1D, Phase 1), GNTI-148 (allogeneic, T1D), GNTI-932 (allogeneic, IBD, under Bristol Myers Squibb collaboration), GNTI-350 (allogeneic CD19 CAR-Treg for B/T cell-mediated autoimmune disease), and GNTI-823 (allogeneic, acute inflammatory and ischemic disease).

GentiBio operates a pre-revenue, capital-intensive clinical development model. The company has raised approximately $177 million across a $20M seed round (August 2020) and a $157M Series A (August 2021), supplemented by non-dilutive grants from Breakthrough T1D and the Helmsley Charitable Trust. There are no commercialized products and no disclosed pricing. The current go-to-market motion is enterprise-oriented clinical execution: a Phase 1 trial enrolling across ten specialized U.S. clinical sites, GMP viral vector supply through Forge Biologics, and strategic collaboration with Bristol Myers Squibb for IBD development. End customers, post-approval, will be payers and patients in autoimmune and inflammatory disease populations. The company is headquartered in Cambridge, Massachusetts, with a Seattle, Washington office and 51-100 employees, and is led by CEO Andy Walker, PhD, with Mark Bach as CMO and Tom Wickham as CSO.

The business is anchored by a top-tier founding investor syndicate (OrbiMed, Novartis Venture Fund, RA Capital Management) with participation from Matrix Capital Management, Avidity Partners, and JDRF T1D Fund (now Breakthrough T1D). Scientific founders David Rawlings (Seattle Children's Research Institute) and Jane Buckner (Benaroya Research Institute) provide foundational IP and translational expertise. Key near-term value drivers are POLARIS Phase 1 data readouts scheduled for late 2026 and first half of 2027, which will determine whether the EngTreg platform achieves clinical proof-of-concept in Type 1 Diabetes and supports progression of the broader allogeneic pipeline.

Short descriptiontext

GentiBio is a clinical-stage biopharmaceutical company developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with lead candidate GNTI-122 in Phase 1 trials for recently diagnosed Type 1 Diabetes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered treg therapies, cell therapy platform, autoimmune disease therapeutics, regulatory t cell therapy, allogeneic cell therapy
Industry3 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical / Cell Therapy Development
TypeOne Time License
Description

GentiBio is a clinical-stage biotechnology company developing engineered Treg therapies as investigational drugs. Revenue will be generated through product sales following regulatory approval. The company has no commercialized products yet and is pre-revenue.

gentibio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GentiBio develops engineered regulatory T cell (EngTreg) therapies as investigational drugs targeting the root cause of autoimmune and inflammatory diseases. Its modular platform combines CAR/TCR targeting, constitutive FOXP3 expression, and proprietary CISC IL-2 signaling technology to create autologous and allogeneic Treg products. The lead candidate GNTI-122 is in the POLARIS Phase 1 clinical trial for recently diagnosed Type 1 Diabetes, with additional allogeneic programs in T1D (GNTI-148), IBD (GNTI-932), B/T cell-driven autoimmune disease (GNTI-350), and acute inflammatory/ischemic disease (GNTI-823).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Autologous manufacturing: >10^9 cells at >90% purity in two weeks, without cell sorting
+2 more records
Product overview1 text field

GentiBio is a clinical-stage biotechnology company developing engineered regulatory T cell (EngTreg) therapies to cure Type 1 diabetes and other autoimmune or acute inflammatory diseases. The company's integrated platform consists of three core technology pillars: (1) the EngTreg Platform for engineered Tregs with specificity, stability, and survival properties; (2) the Off-the-shelf Allogeneic Platform with immune evasive engineering for ready-to-use cell therapies; and (3) Scalable Manufacturing Platform supporting both autologous and allogeneic products. The product pipeline includes five distinct therapeutic candidates: GNTI-122 (autologous EngTreg for Type 1 Diabetes, in Phase 1 POLARIS trial), GNTI-148 (allogeneic version of GNTI-122 for T1D), GNTI-932 (allogeneic gut-targeted CAR EngTreg for Inflammatory Bowel Disease), GNTI-350 (allogeneic CD19 CAR EngTreg for B/T cell-mediated autoimmune diseases), and GNTI-823 (allogeneic tissue Treg for acute inflammatory and ischemic diseases).

Product and service2 records
1GNTI-122
CategoryEngineered regulatory T cell therapy (autologous)
Description

An autologous engineered regulatory T cell (EngTreg) product designed to treat recently diagnosed Type 1 Diabetes by expressing a pancreatic islet-specific T cell receptor (TCR) to target the pancreas, with modifications to stabilize FOXP3 protein and a chimeric IL-2 signaling complex (CISC) for proliferative support. Currently in the Phase 1 POLARIS clinical trial; FDA Orphan Drug Designation granted July 2025 and FDA Fast Track Designation granted August 2025.

2GNTI-148
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCore Scientific CollaboratorTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

BRI is a foundational scientific collaborator with GentiBio. Dr. Jane Buckner (President of BRI and Scientific Co-founder) contributed foundational discoveries on T cell receptors and patient-derived suppression assays. BRI provides ongoing expertise in human immunology and autoimmune disease biology supporting GNTI-122 development.

Strategic tierCore Scientific CollaboratorTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

SCRI is a foundational scientific collaborator with GentiBio. Dr. David Rawlings (Director, Center for Immunity and Immunotherapies and Scientific Co-founder) developed methods to generate stable regulatory T cells by enforcing FOXP3 expression and the CISC technology. SCRI contributes ongoing expertise in immunology and immunotherapy translation.

3Bristol Myers Squibb
Strategic tierStrategic CollaborationTypeStrategic or Co-development PartnerAnnounced on2022-08-10
Description

GentiBio announced a collaboration with Bristol Myers Squibb to pioneer engineered Treg therapies for inflammatory bowel diseases (IBD), leveraging GentiBio's EngTreg platform for gut-specific therapeutic development.

gentibio.com
Strategic tierCdmo PartnerTypeTechnology or IntegrationAnnounced on2021-07-15
Description

GentiBio entered into a partnership with Forge Biologics for viral vector contract development and GMP manufacturing. Forge Biologics serves as a contract development and manufacturing organization (CDMO) supporting GentiBio's cell therapy pipeline.

5MIGAL Galilee Research Institute
Strategic tierResearch CollaboratorTypeTechnology or IntegrationAnnounced on2020-10-28
Description

GentiBio expanded its leadership team and partnership with MIGAL (Galilee Research Institute) to help advance the development of engineered regulatory T cell therapies.

gentibio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sonoma Biotherapeutics is a clinical-stage Treg cell therapy company developing engineered regulatory T cells for autoimmune and inflammatory diseases, including rheumatology and IBD indications. It is the closest direct competitor to GentiBio given shared Treg engineering modality, disease focus, and clinical-stage status.

TypeDirect peer
Description

Kyverna Therapeutics develops CAR-Treg cell therapies for autoimmune diseases, with lead programs in lupus nephritis and other B-cell-mediated autoimmune indications. It competes directly with GentiBio's GNTI-350 in CD19-directed Treg approaches and shares the engineered-Treg modality.

TypeDirect peer
Description

Quell Therapeutics is a clinical-stage cell therapy company developing engineered Treg therapies, with lead programs in liver transplant tolerance and autoimmune diseases. It shares GentiBio's Treg modality and autoimmune focus, making it a direct European-headquartered peer.

TypeEmerging player
Description

Egle Therapeutics is an emerging Treg-focused biotech developing engineered regulatory T cells for autoimmune and inflammatory diseases, based on proprietary FOXP3 stabilization approaches. It overlaps with GentiBio's FOXP3 engineering pillar and indications in autoimmunity.

5Bristol Myers Squibb
TypeBroad incumbent
Description

BMS is a global pharmaceutical company with established CAR-T franchises (Breyanzi, Abecma) and an active autoimmune pipeline, and is GentiBio's strategic collaborator on the IBD EngTreg program (GNTI-932). It is a broad incumbent in cell therapy and a potential acquirer/long-term partner for GentiBio's allogeneic platform.

TypeEmerging player
Description

Vertex has advanced a stem cell-derived islet cell therapy (VX-880/zimislecel) into clinical trials for Type 1 Diabetes, pursuing a beta-cell replacement rather than immune-modulation approach. It is a relevant T1D peer because it competes for the same patient population and KOL attention as GNTI-122.

TypeEmerging player
Description

BlueRock Therapeutics (a Bayer company) develops iPSC-derived cell therapies, with a lead program in Parkinson's disease and ongoing immunology applications. It is a peer in engineered cell therapy manufacturing scale-up and has overlapping scientific approaches (iPSC-derived Tregs were previously explored at BlueRock).

TypeEmerging player
Description

Sana Biotechnology is a clinical-stage cell therapy company developing hypoimmune allogeneic cell therapies and in vivo gene editing approaches, with applications in autoimmune and oncology indications. It is an emerging peer in engineered cell therapy with overlapping allogeneic hypoimmune engineering concepts.

TypeEmerging player
Description

Allogene Therapeutics is a clinical-stage allogeneic CAR-T company with leading manufacturing capabilities for off-the-shelf cell therapies. It is comparable as a peer in allogeneic cell therapy scale-up, manufacturing economics, and regulatory navigation, though focused on oncology indications.

TypeOthers
Description

Provention Bio (acquired by Sanofi in 2023) developed teplizumab (Tzield), the first FDA-approved disease-modifying therapy for T1D, used to delay Stage 3 onset in at-risk patients. It is a relevant T1D adjacency because Tzield defines the existing standard of care that GNTI-122 would need to displace or complement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GentiBio

Cell Therapy Biopharmaceuticalsgentibio.com

GentiBio is a clinical-stage biopharmaceutical company developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with lead candidate GNTI-122 in Phase 1 trials for recently diagnosed Type 1 Diabetes.

What GentiBio does

GentiBio is a clinical-stage biopharmaceutical company developing engineered regulatory T cell (EngTreg) therapies to treat autoimmune and inflammatory diseases, with its lead candidate GNTI-122 currently in the Phase 1 POLARIS trial for recently diagnosed Type 1 Diabetes. The company's scientific foundation rests on a modular EngTreg platform that combines three technology pillars: targeting via CAR, TCR, or chemokine receptors for disease-site specificity; constitutive FOXP3 expression to lock in a durable Treg phenotype in inflammatory environments; and a proprietary Chimeric IL-2 Signaling Complex (CISC) that provides IL-2 survival support specifically to engineered cells. The platform extends to an off-the-shelf allogeneic format enabled by Immune Evasion Engineering (HLA knock-out combined with a proprietary NK inhibitor) and a scalable manufacturing system that delivers >10^9 autologous cells at >90% purity in two weeks or thousands of allogeneic doses per batch at low-thousands-of-dollars COGS. The pipeline includes GNTI-122 (autologous, T1D, Phase 1), GNTI-148 (allogeneic, T1D), GNTI-932 (allogeneic, IBD, under Bristol Myers Squibb collaboration), GNTI-350 (allogeneic CD19 CAR-Treg for B/T cell-mediated autoimmune disease), and GNTI-823 (allogeneic, acute inflammatory and ischemic disease).

GentiBio operates a pre-revenue, capital-intensive clinical development model. The company has raised approximately $177 million across a $20M seed round (August 2020) and a $157M Series A (August 2021), supplemented by non-dilutive grants from Breakthrough T1D and the Helmsley Charitable Trust. There are no commercialized products and no disclosed pricing. The current go-to-market motion is enterprise-oriented clinical execution: a Phase 1 trial enrolling across ten specialized U.S. clinical sites, GMP viral vector supply through Forge Biologics, and strategic collaboration with Bristol Myers Squibb for IBD development. End customers, post-approval, will be payers and patients in autoimmune and inflammatory disease populations. The company is headquartered in Cambridge, Massachusetts, with a Seattle, Washington office and 51-100 employees, and is led by CEO Andy Walker, PhD, with Mark Bach as CMO and Tom Wickham as CSO.

The business is anchored by a top-tier founding investor syndicate (OrbiMed, Novartis Venture Fund, RA Capital Management) with participation from Matrix Capital Management, Avidity Partners, and JDRF T1D Fund (now Breakthrough T1D). Scientific founders David Rawlings (Seattle Children's Research Institute) and Jane Buckner (Benaroya Research Institute) provide foundational IP and translational expertise. Key near-term value drivers are POLARIS Phase 1 data readouts scheduled for late 2026 and first half of 2027, which will determine whether the EngTreg platform achieves clinical proof-of-concept in Type 1 Diabetes and supports progression of the broader allogeneic pipeline.

GentiBio firmographics

Firmographics
Name
GentiBio
Legal name
GentiBio, Inc.
Website
https://gentibio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
GentiBio is a clinical-stage biopharmaceutical company developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with lead candidate GNTI-122 in Phase 1 trials for recently diagnosed Type 1 Diabetes.
Ownership category
akta.pro rank

GentiBio industry classification

Industry
Product category
Cell Therapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Engineered treg therapies
  • Cell therapy platform
  • Autoimmune disease therapeutics
  • Regulatory t cell therapy
  • Allogeneic cell therapy

Where GentiBio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

GentiBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical / Cell Therapy Development: GentiBio is a clinical-stage biotechnology company developing engineered Treg therapies as investigational drugs. Revenue will be generated through product sales following regulatory approval. The company has no commercialized products yet and is pre-revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

GentiBio product offering

Product offering

Core offering

GentiBio develops engineered regulatory T cell (EngTreg) therapies as investigational drugs targeting the root cause of autoimmune and inflammatory diseases. Its modular platform combines CAR/TCR targeting, constitutive FOXP3 expression, and proprietary CISC IL-2 signaling technology to create autologous and allogeneic Treg products. The lead candidate GNTI-122 is in the POLARIS Phase 1 clinical trial for recently diagnosed Type 1 Diabetes, with additional allogeneic programs in T1D (GNTI-148), IBD (GNTI-932), B/T cell-driven autoimmune disease (GNTI-350), and acute inflammatory/ischemic disease (GNTI-823).

Product overview

GentiBio is a clinical-stage biotechnology company developing engineered regulatory T cell (EngTreg) therapies to cure Type 1 diabetes and other autoimmune or acute inflammatory diseases. The company's integrated platform consists of three core technology pillars: (1) the EngTreg Platform for engineered Tregs with specificity, stability, and survival properties; (2) the Off-the-shelf Allogeneic Platform with immune evasive engineering for ready-to-use cell therapies; and (3) Scalable Manufacturing Platform supporting both autologous and allogeneic products. The product pipeline includes five distinct therapeutic candidates: GNTI-122 (autologous EngTreg for Type 1 Diabetes, in Phase 1 POLARIS trial), GNTI-148 (allogeneic version of GNTI-122 for T1D), GNTI-932 (allogeneic gut-targeted CAR EngTreg for Inflammatory Bowel Disease), GNTI-350 (allogeneic CD19 CAR EngTreg for B/T cell-mediated autoimmune diseases), and GNTI-823 (allogeneic tissue Treg for acute inflammatory and ischemic diseases).

Differentiator

Problem solved

Functional benefit

Products and services

  • GNTI-122 An autologous engineered regulatory T cell (EngTreg) product designed to treat recently diagnosed Type 1 Diabetes by expressing a pancreatic islet-specific T cell receptor (TCR) to target the pancreas, with modifications to stabilize FOXP3 protein and a chimeric IL-2 signaling complex (CISC) for proliferative support. Currently in the Phase 1 POLARIS clinical trial; FDA Orphan Drug Designation granted July 2025 and FDA Fast Track Designation granted August 2025.
  • GNTI-148

Quantifiable outcome

  • Autologous manufacturing: >10^9 cells at >90% purity in two weeks, without cell sorting
  • +2 more outcomes

Companies that use GentiBio

Customer profile

Segments4 records

Ideal customer profiles4 records

GentiBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

GentiBio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core scientific collaborator, strategic collaboration, cdmo partner and research collaborator.

  • Benaroya Research Institute at Virginia Mason Franciscan Health (BRI)core scientific collaboratorStrategic or Co-development Partner · 23 April 2026BRI is a foundational scientific collaborator with GentiBio. Dr. Jane Buckner (President of BRI and Scientific Co-founder) contributed foundational discoveries on T cell receptors and patient-derived suppression assays. BRI provides ongoing expertise in human immunology and autoimmune disease biology supporting GNTI-122 development.
  • Seattle Children's Research Institute (SCRI)core scientific collaboratorStrategic or Co-development Partner · 23 April 2026SCRI is a foundational scientific collaborator with GentiBio. Dr. David Rawlings (Director, Center for Immunity and Immunotherapies and Scientific Co-founder) developed methods to generate stable regulatory T cells by enforcing FOXP3 expression and the CISC technology. SCRI contributes ongoing expertise in immunology and immunotherapy translation.
  • Bristol Myers Squibbstrategic collaborationStrategic or Co-development Partner · 10 August 2022GentiBio announced a collaboration with Bristol Myers Squibb to pioneer engineered Treg therapies for inflammatory bowel diseases (IBD), leveraging GentiBio's EngTreg platform for gut-specific therapeutic development.
  • Forge Biologicscdmo partnerTechnology or Integration · 15 July 2021GentiBio entered into a partnership with Forge Biologics for viral vector contract development and GMP manufacturing. Forge Biologics serves as a contract development and manufacturing organization (CDMO) supporting GentiBio's cell therapy pipeline.
  • MIGAL Galilee Research Instituteresearch collaboratorTechnology or Integration · 28 October 2020GentiBio expanded its leadership team and partnership with MIGAL (Galilee Research Institute) to help advance the development of engineered regulatory T cell therapies.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

GentiBio competitors and assessment

Company assessment

Direct peers

  • Sonoma Biotherapeutics: Sonoma Biotherapeutics is a clinical-stage Treg cell therapy company developing engineered regulatory T cells for autoimmune and inflammatory diseases, including rheumatology and IBD indications. It is the closest direct competitor to GentiBio given shared Treg engineering modality, disease focus, and clinical-stage status.
  • Kyverna Therapeutics: Kyverna Therapeutics develops CAR-Treg cell therapies for autoimmune diseases, with lead programs in lupus nephritis and other B-cell-mediated autoimmune indications. It competes directly with GentiBio's GNTI-350 in CD19-directed Treg approaches and shares the engineered-Treg modality.
  • Quell Therapeutics: Quell Therapeutics is a clinical-stage cell therapy company developing engineered Treg therapies, with lead programs in liver transplant tolerance and autoimmune diseases. It shares GentiBio's Treg modality and autoimmune focus, making it a direct European-headquartered peer.

Emerging players

  • Egle Therapeutics: Egle Therapeutics is an emerging Treg-focused biotech developing engineered regulatory T cells for autoimmune and inflammatory diseases, based on proprietary FOXP3 stabilization approaches. It overlaps with GentiBio's FOXP3 engineering pillar and indications in autoimmunity.
  • Vertex Pharmaceuticals: Vertex has advanced a stem cell-derived islet cell therapy (VX-880/zimislecel) into clinical trials for Type 1 Diabetes, pursuing a beta-cell replacement rather than immune-modulation approach. It is a relevant T1D peer because it competes for the same patient population and KOL attention as GNTI-122.
  • BlueRock Therapeutics: BlueRock Therapeutics (a Bayer company) develops iPSC-derived cell therapies, with a lead program in Parkinson's disease and ongoing immunology applications. It is a peer in engineered cell therapy manufacturing scale-up and has overlapping scientific approaches (iPSC-derived Tregs were previously explored at BlueRock).
  • Sana Biotechnology: Sana Biotechnology is a clinical-stage cell therapy company developing hypoimmune allogeneic cell therapies and in vivo gene editing approaches, with applications in autoimmune and oncology indications. It is an emerging peer in engineered cell therapy with overlapping allogeneic hypoimmune engineering concepts.
  • Allogene Therapeutics: Allogene Therapeutics is a clinical-stage allogeneic CAR-T company with leading manufacturing capabilities for off-the-shelf cell therapies. It is comparable as a peer in allogeneic cell therapy scale-up, manufacturing economics, and regulatory navigation, though focused on oncology indications.

Broad incumbents

  • Bristol Myers Squibb: BMS is a global pharmaceutical company with established CAR-T franchises (Breyanzi, Abecma) and an active autoimmune pipeline, and is GentiBio's strategic collaborator on the IBD EngTreg program (GNTI-932). It is a broad incumbent in cell therapy and a potential acquirer/long-term partner for GentiBio's allogeneic platform.

Others

  • Provention Bio (Sanofi): Provention Bio (acquired by Sanofi in 2023) developed teplizumab (Tzield), the first FDA-approved disease-modifying therapy for T1D, used to delay Stage 3 onset in at-risk patients. It is a relevant T1D adjacency because Tzield defines the existing standard of care that GNTI-122 would need to displace or complement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

GentiBio social profiles

Digital presence

GentiBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GentiBio leadership team

Management profile

Number of profiles

Profiles15 records

GentiBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GentiBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GentiBio

What does GentiBio do?

GentiBio develops engineered regulatory T cell (EngTreg) therapies as investigational drugs targeting the root cause of autoimmune and inflammatory diseases. Its modular platform combines CAR/TCR targeting, constitutive FOXP3 expression, and proprietary CISC IL-2 signaling technology to create autologous and allogeneic Treg products. The lead candidate GNTI-122 is in the POLARIS Phase 1 clinical trial for recently diagnosed Type 1 Diabetes, with additional allogeneic programs in T1D (GNTI-148), IBD (GNTI-932), B/T cell-driven autoimmune disease (GNTI-350), and acute inflammatory/ischemic disease (GNTI-823).

Is GentiBio a public or private company?

GentiBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was GentiBio founded?

GentiBio was founded in 2020. It employs 11 to 50 people.

Where is GentiBio based?

GentiBio is headquartered in Cambridge, United States, in the North America region.

How does GentiBio make money?

One revenue line is on record: biopharmaceutical / Cell Therapy Development.

Who are GentiBio's main competitors?

Direct peers on record are Sonoma Biotherapeutics, Kyverna Therapeutics and Quell Therapeutics. Emerging players are Egle Therapeutics, Vertex Pharmaceuticals, BlueRock Therapeutics, Sana Biotechnology and Allogene Therapeutics. Bristol Myers Squibb is listed as a broad incumbent. Provention Bio (Sanofi) is listed as an others.

Does GentiBio have an API?

No public API is recorded for GentiBio.

What industry is GentiBio in?

GentiBio's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SeattlechildrensChildren’s Researchers Share Progress at American Society of GeneSeattle Children’s Research Institute showcased pivotal research advancements in gene and cell therapies at the American Society of Gene and Cell Therapy Annual Meeting in Los Angeles. The institute's labs are collaborating with biotechnology startups GentiBio and Be Biopharma to advance engineered cell therapies for conditions including cancer, Type 1 diabetes, and hemophilia toward human clinical trials.BioSpaceGentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 DiabetesGentiBio announced that the first participant has been dosed in POLARIS, a Phase 1 clinical trial evaluating GNTI-122, an engineered regulatory T cell therapy for adults recently diagnosed with type 1 diabetes. The trial is enrolling at 10 specialized clinical sites across the U.S., with the first patient dosed at the University of North Carolina, Chapel Hill. The company expects to present key data from the study in late 2026 and the first half of 2027.PR NewswireGentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 DiabetesGentiBio announced that the first participant has been dosed in POLARIS, a Phase 1 clinical trial evaluating GNTI-122, an engineered regulatory T cell therapy for adults recently diagnosed with type 1 diabetes. The trial is enrolling at 10 specialized clinical sites across the U.S., with the first patient dosed at the University of North Carolina, Chapel Hill. The company expects to present key data from the study in late 2026 and the first half of 2027, with the therapy designed to potentially eliminate the need for lifelong insulin injections by halting the autoimmune attack on insulin-producing cells.PR NewswireGentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical OfficerGentiBio, a Cambridge-based cell and gene therapy company specializing in engineered regulatory T cells, appointed Mark Bach as Chief Medical Officer. Dr. Bach brings over 30 years of clinical research and development experience and previously served as CMO at Structure Therapeutics, with senior roles at Ascendis Pharma, Janssen/Johnson & Johnson, and Merck. The appointment is timed with GentiBio's lead asset GNTI-122 advancing toward clinical trials in 2025 for Type 1 Diabetes, positioning the company to enter the clinical-stage phase of development.American City Business JournalsBiotech layoffs 2023: GentiBio cuts workers months after $1.9B deal with Bristol MyersGentiBio, a Boston-based biotech startup, cut workers months after a $1.9B deal with Bristol Myers. The company blamed the layoffs on a challenging biotech macroenvironment.BioSpaceBioSpace NextGen Bio 2022 Winners: Where are They Now?BioSpace's NextGen Bio 2022 companies have advanced since their January list, with Orna validating its circular RNA platform and securing a $3.5B Merck deal, GentiBio partnering with BMS, and Prime editing company Prime filing for an IPO. Other companies like AavantiBio merged with Solid Biosciences, while Graphite Bio dosed its first patient in a sickle cell trial.American City Business JournalsImmunology startup GentiBio signs $1.9B deal with Bristol MyersImmunology startup GentiBio signed a collaboration deal with Bristol Myers, valued at up to $1.9 billion. The deal was announced on August 10, 2022, when the company was two years old.BioSpaceBMS Bets up to $1.9 Billion on GentiBio’s Treg Platform for IBDBristol Myers Squibb and GentiBio are partnering to develop engineered Treg therapies for inflammatory bowel disease, with GentiBio receiving up to $1.9 billion in milestone and royalty payments. The collaboration aims to provide a functional cure by repairing gut tissue and restoring immune tolerance, with BMS eligible to advance up to three programs into clinical trials.BioPharma DiveGentiBio partners with Bristol Myers as cell therapy for immune disease gains momentumBiotechnology startup GentiBio announced a partnership with Bristol Myers Squibb to develop a cell therapy for inflammatory bowel disease, with Bristol Myers gaining rights to advance up to three programs into clinical testing. GentiBio will receive an unspecified upfront payment and potentially up to $1.9 billion in development and sales milestones. The Boston-based company, backed by Novartis Ventures, has raised $177 million since its launch two years ago.PR NewswireGentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel DiseasesGentiBio and Bristol Myers Squibb announced a collaboration to develop engineered Treg therapies for inflammatory bowel diseases. Bristol Myers Squibb made an undisclosed upfront cash payment, and GentiBio is eligible for up to $1.9 billion in development and commercial milestones plus royalties.